$RVMD
Revolution Medicines, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023059391 Filed on November 06, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $742.0K $0.00 $3.356M
YoY Change -95.16% -100.0% 204.81%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $32.24M $15.51M $10.43M
YoY Change 195.55% 48.65% 33.92%
% of Gross Profit
Research & Development $148.5M $107.7M $69.46M
YoY Change 124.54% 55.11% 49.45%
% of Gross Profit
Depreciation & Amortization $1.610M $1.300M $1.258M
YoY Change 13.62% 3.34% 18.68%
% of Gross Profit
Operating Expenses $180.7M $123.2M $79.89M
YoY Change 134.6% 54.27% 47.22%
Operating Profit -$123.2M -$76.53M
YoY Change 61.04% 43.96%
Interest Expense $18.67M $10.95M $0.00
YoY Change 267.82% -100.0%
% of Operating Profit
Other Income/Expense, Net $115.0K $10.95M $2.907M
YoY Change 276.57% 1203.59%
Pretax Income -$161.2M -$112.3M -$73.63M
YoY Change 184.64% 52.53% 39.07%
Income Tax $343.0K -$3.867M -$297.0K
% Of Pretax Income
Net Earnings -$161.5M -$108.4M -$73.33M
YoY Change 185.87% 47.87% 38.51%
Net Earnings / Revenue -21770.49% -2185.01%
Basic Earnings Per Share -$0.99 -$0.87
Diluted Earnings Per Share -$1.14 -$0.99 -$0.87
COMMON SHARES
Basic Shares Outstanding 109.6M 109.2M 84.69M
Diluted Shares Outstanding 109.2M 84.69M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.853B $813.2M $655.0M
YoY Change 187.31% 24.15% 7.62%
Cash & Equivalents $696.1M $358.4M $178.9M
Short-Term Investments $1.157B $454.8M $476.1M
Other Short-Term Assets $25.07M $11.00M $15.16M
YoY Change 137.22% -27.42% 102.91%
Inventory
Prepaid Expenses
Receivables $1.254M $300.0K $4.940M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.879B $824.5M $675.1M
YoY Change 184.66% 22.12% 8.27%
LONG-TERM ASSETS
Property, Plant & Equipment $22.87M $20.29M $18.27M
YoY Change 22.54% 11.05% 80.74%
Goodwill $14.61M $14.61M $14.61M
YoY Change 0.0% 0.0% 0.0%
Intangibles $57.74M $58.01M $59.08M
YoY Change -1.82% -1.81% -1.78%
Long-Term Investments
YoY Change
Other Assets $7.032M $11.35M $856.0K
YoY Change 146.13% 1226.17% -36.5%
Total Long-Term Assets $182.4M $159.8M $150.8M
YoY Change 20.22% 5.94% 35.32%
TOTAL ASSETS
Total Short-Term Assets $1.879B $824.5M $675.1M
Total Long-Term Assets $182.4M $159.8M $150.8M
Total Assets $2.062B $984.2M $825.9M
YoY Change 153.93% 19.17% 12.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $61.79M $29.63M $24.38M
YoY Change 190.0% 21.51% 132.41%
Accrued Expenses $78.17M $55.40M $38.72M
YoY Change 118.87% 43.1% 35.32%
Deferred Revenue $0.00 $0.00 $9.686M
YoY Change -100.0% -100.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $143.9M $85.54M $73.27M
YoY Change 132.08% 16.75% 41.2%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.458M $982.0K $471.0K
YoY Change 384.39% 108.49% -98.74%
Total Long-Term Liabilities $1.458M $982.0K $471.0K
YoY Change 384.39% 108.49% -98.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $143.9M $85.54M $73.27M
Total Long-Term Liabilities $1.458M $982.0K $471.0K
Total Liabilities $235.5M $146.8M $144.5M
YoY Change 85.82% 1.58% 49.31%
SHAREHOLDERS EQUITY
Retained Earnings -$1.100B -$976.2M -$644.8M
YoY Change 56.85% 51.4% 61.2%
Common Stock $2.963B $1.815B $1.329B
YoY Change 113.45% 36.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.826B $837.5M $681.4M
YoY Change
Total Liabilities & Shareholders Equity $2.062B $984.2M $825.9M
YoY Change 153.93% 19.17% 12.37%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$161.5M -$108.4M -$73.33M
YoY Change 185.87% 47.87% 38.51%
Depreciation, Depletion And Amortization $1.610M $1.300M $1.258M
YoY Change 13.62% 3.34% 18.68%
Cash From Operating Activities -$120.6M -$100.5M -$51.74M
YoY Change 95.12% 94.25% 41.4%
INVESTING ACTIVITIES
Capital Expenditures $2.319M $2.530M -$3.525M
YoY Change -19.37% -171.77% 676.43%
Acquisitions
YoY Change
Other Investing Activities -$378.1M $79.89M -$119.9M
YoY Change 8842.5% -166.62% 303.44%
Cash From Investing Activities -$380.4M $77.35M -$123.4M
YoY Change 5254.7% -162.66% 309.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 839.4M 1.010M 248.3M
YoY Change 1534.15% -99.59% 77747.96%
NET CHANGE
Cash From Operating Activities -120.6M -100.5M -51.74M
Cash From Investing Activities -380.4M 77.35M -123.4M
Cash From Financing Activities 839.4M 1.010M 248.3M
Net Change In Cash 338.4M -22.14M 73.16M
YoY Change -2030.46% -130.26% -210.1%
FREE CASH FLOW
Cash From Operating Activities -$120.6M -$100.5M -$51.74M
Capital Expenditures $2.319M $2.530M -$3.525M
Free Cash Flow -$122.9M -$103.0M -$48.21M
YoY Change 90.03% 113.7% 33.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001628171
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://www.revolutionmedicines.com/20230930#CollaborationRevenueMember
CY2022Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://www.revolutionmedicines.com/20230930#CollaborationRevenueMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://www.revolutionmedicines.com/20230930#CollaborationRevenueMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://www.revolutionmedicines.com/20230930#CollaborationRevenueMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39219
dei Entity Registrant Name
EntityRegistrantName
Revolution Medicines, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2029180
dei Entity Address Address Line1
EntityAddressAddressLine1
700 Saginaw Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94063
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
481-6801
dei Security12b Title
Security12bTitle
Common Stock $0.0001 Par Value per Share
dei Trading Symbol
TradingSymbol
RVMD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
109564695
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
358399000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
161412000
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
454796000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
483531000
CY2023Q3 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
309000
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
4673000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10963000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10569000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
824467000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
660185000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20286000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18659000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
53122000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
55077000
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
58006000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
58807000
CY2023Q3 us-gaap Goodwill
Goodwill
14608000
CY2022Q4 us-gaap Goodwill
Goodwill
14608000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2391000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1737000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11352000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2857000
CY2023Q3 us-gaap Assets
Assets
984232000
CY2022Q4 us-gaap Assets
Assets
811930000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
29627000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
21306000
CY2023Q3 rvmd Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
50159000
CY2022Q4 rvmd Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
29446000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5755000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6773000
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4459000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
85541000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
61984000
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3158000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
7025000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
57093000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
57432000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
982000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
301000
CY2023Q3 us-gaap Liabilities
Liabilities
146774000
CY2022Q4 us-gaap Liabilities
Liabilities
126742000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
109451685
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
109451685
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
90411912
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
90411912
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
11000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
9000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1814489000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1388300000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-871000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1780000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-976171000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-701341000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
837458000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
685188000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
984232000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
811930000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3356000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10838000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20050000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3356000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10838000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20050000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
107735000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69455000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
274663000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
186946000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15513000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10434000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
43377000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29676000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
123248000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
79889000
us-gaap Operating Expenses
OperatingExpenses
318040000
us-gaap Operating Expenses
OperatingExpenses
216622000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-123248000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-76533000
us-gaap Operating Income Loss
OperatingIncomeLoss
-307202000
us-gaap Operating Income Loss
OperatingIncomeLoss
-196572000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
10947000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2907000
us-gaap Investment Income Interest
InvestmentIncomeInterest
28505000
us-gaap Investment Income Interest
InvestmentIncomeInterest
4077000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10947000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2907000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
28505000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4077000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-112301000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-73626000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-278697000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-192495000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3867000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-297000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3867000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-297000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-108434000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-73329000
us-gaap Net Income Loss
NetIncomeLoss
-274830000
us-gaap Net Income Loss
NetIncomeLoss
-192198000
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.99
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.99
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.47
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.47
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109233084
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109233084
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
84694860
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
84694860
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
103702501
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
103702501
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77751185
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77751185
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-108434000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-73329000
us-gaap Net Income Loss
NetIncomeLoss
-274830000
us-gaap Net Income Loss
NetIncomeLoss
-192198000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
380000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-654000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
909000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2043000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-108054000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-73983000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-273921000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-194241000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
685188000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
499000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9699000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1224000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-68098000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
952218000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
468000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2109000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12980000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-695000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-98298000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
930835000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1011000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13666000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
380000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-108434000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
837458000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
602568000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
305000
CY2022Q1 rvmd Adjustments To Additional Paid In Capital Vesting Of Early Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExerciseOfStockOptions
31000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6644000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-908000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-57647000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
550993000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
190000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1239000
CY2022Q2 rvmd Adjustments To Additional Paid In Capital Vesting Of Early Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExerciseOfStockOptions
24000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8098000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-481000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-61222000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
498841000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
209000
CY2022Q3 rvmd Adjustments To Additional Paid In Capital Vesting Of Early Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExerciseOfStockOptions
88000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8138000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-654000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-73329000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
681419000
us-gaap Profit Loss
ProfitLoss
-274830000
us-gaap Profit Loss
ProfitLoss
-192198000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-19000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
801000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
801000
us-gaap Share Based Compensation
ShareBasedCompensation
36345000
us-gaap Share Based Compensation
ShareBasedCompensation
22880000
us-gaap Depreciation
Depreciation
3695000
us-gaap Depreciation
Depreciation
2823000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
13572000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
486000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1955000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
3433000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4364000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-989000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
394000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8365000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8164000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8795000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
20959000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
4468000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4459000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3827000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1357000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1433000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
3867000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
296000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
8495000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
196000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
681000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-20000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-230009000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-162613000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
539311000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
452434000
rvmd Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
582527000
rvmd Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
443362000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5412000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7940000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
37804000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17012000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
323706000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
248126000
rvmd Proceeds From Issuance Of Common Stock From At The Market Offering
ProceedsFromIssuanceOfCommonStockFromAtTheMarketOffering
62053000
rvmd Proceeds From Issuance Of Common Stock From At The Market Offering
ProceedsFromIssuanceOfCommonStockFromAtTheMarketOffering
0
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1978000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
704000
rvmd Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
2109000
rvmd Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
1239000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
389846000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
250069000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
197641000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
70444000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
163149000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
110234000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
360790000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
180678000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
358399000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
178941000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
2391000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
1737000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
360790000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
180678000
rvmd Vesting Of Early Exercised Options And Restricted Stock
VestingOfEarlyExercisedOptionsAndRestrictedStock
0
rvmd Vesting Of Early Exercised Options And Restricted Stock
VestingOfEarlyExercisedOptionsAndRestrictedStock
143000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1329000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2754000
rvmd Unpaid Deferred Offering Costs
UnpaidDeferredOfferingCosts
3000
rvmd Unpaid Deferred Offering Costs
UnpaidDeferredOfferingCosts
0
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-976200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, clinical accruals, valuation of in-process research and development and developed technologies, income taxes, useful lives of property and equipment and intangible assets, impairment of goodwill and intangibles, impairment of in-process research and development and developed technologies, the incremental borrowing rate for determining operating lease assets and liabilities and stock-based compensation. The extent to which the COVID-19 pandemic may directly or indirectly impact the Company’s business, financial condition and results of operations is highly uncertain and subject to change. The Company considered the potential impact of the COVID-19 pandemic on its estimates and assumptions and there was not a material impact to the Company’s unaudited condensed consolidated financial statements as of and for the three and nine months ended September 30, 2023. Actual results could materially differ from the Company’s estimates, and there may be changes to the estimates in future periods</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span>
CY2022Q3 us-gaap Depreciation
Depreciation
1000000
us-gaap Depreciation
Depreciation
3700000
us-gaap Depreciation
Depreciation
2800000
CY2023Q3 rvmd Fair Value Level1 Level2 Level3 Transfers Amount
FairValueLevel1Level2Level3TransfersAmount
0
CY2022Q4 rvmd Fair Value Level1 Level2 Level3 Transfers Amount
FairValueLevel1Level2Level3TransfersAmount
0
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
810738000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
25000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
896000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
809867000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
647465000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
47000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1827000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
645685000
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
810738000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
25000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
896000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
809867000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
38368000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
33148000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
18082000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14489000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20286000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18659000
CY2023Q3 us-gaap Depreciation
Depreciation
1300000
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
12828000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
13281000
CY2023Q3 rvmd Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
34981000
CY2022Q4 rvmd Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
15161000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1870000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
499000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
480000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
505000
CY2023Q3 rvmd Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
50159000
CY2022Q4 rvmd Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
29446000
CY2023Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
55800000
CY2023Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
55800000
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7480000
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5274000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2206000
CY2023Q3 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P2Y1M6D
CY2023Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
63280000
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5274000
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
58006000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
800000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
800000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
268000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1069000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
869000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2206000
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
55800000
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
55800000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7480000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4473000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3007000
CY2022Q4 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P2Y10M24D
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
63280000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4473000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
58807000
CY2022Q4 us-gaap Goodwill
Goodwill
14608000
us-gaap Goodwill Translation And Purchase Accounting Adjustments
GoodwillTranslationAndPurchaseAccountingAdjustments
0
CY2023Q3 us-gaap Goodwill
Goodwill
14608000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5755000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6773000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
57093000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
57432000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
62848000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
64205000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1900000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1800000
CY2023Q3 us-gaap Sublease Income
SubleaseIncome
0
CY2022Q3 us-gaap Sublease Income
SubleaseIncome
500000
us-gaap Operating Lease Cost
OperatingLeaseCost
5700000
us-gaap Operating Lease Cost
OperatingLeaseCost
4700000
us-gaap Sublease Income
SubleaseIncome
300000
us-gaap Sublease Income
SubleaseIncome
1200000
CY2023Q3 us-gaap Proceeds From Lease Payments
ProceedsFromLeasePayments
400000
CY2022Q3 us-gaap Proceeds From Lease Payments
ProceedsFromLeasePayments
200000
us-gaap Proceeds From Lease Payments
ProceedsFromLeasePayments
1400000
us-gaap Proceeds From Lease Payments
ProceedsFromLeasePayments
1400000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1729000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
7100000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7349000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
7606000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
7872000
CY2023Q3 rvmd Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
73717000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
105373000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
41525000
CY2023Q3 rvmd Lessee Operating Lease Liability Tenant Improvement Allowance
LesseeOperatingLeaseLiabilityTenantImprovementAllowance
1000000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
62848000
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.084
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12Y3M18D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y10M24D
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote
CY2023Q3 rvmd Number Of Voting Rights Per Common Share
NumberOfVotingRightsPerCommonShare
1
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
84694860
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
103702501
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
103702501
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
22316592
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
17766601
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
82100000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M13D
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13666000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8138000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
36345000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22880000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-108434000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-73329000
us-gaap Net Income Loss
NetIncomeLoss
-274830000
us-gaap Net Income Loss
NetIncomeLoss
-192198000
CY2023Q3 rvmd Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
109233340
CY2022Q3 rvmd Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
84709849
rvmd Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
103704719
rvmd Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
77764196
CY2023Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
256
CY2022Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
14989
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
2218
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
13011
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109233084
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109233084
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
84694860
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77751185
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77751185
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.99
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.99
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.47
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13320179
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9883645

Files In Submission

Name View Source Status
rvmd-20230930_cal.xml Edgar Link unprocessable
rvmd-20230930_def.xml Edgar Link unprocessable
0000950170-23-059391-index-headers.html Edgar Link pending
0000950170-23-059391-index.html Edgar Link pending
0000950170-23-059391.txt Edgar Link pending
0000950170-23-059391-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rvmd-20230930.htm Edgar Link pending
rvmd-20230930.xsd Edgar Link pending
rvmd-ex10_3.htm Edgar Link pending
rvmd-ex31_1.htm Edgar Link pending
rvmd-ex31_2.htm Edgar Link pending
rvmd-ex32_1.htm Edgar Link pending
rvmd-ex32_2.htm Edgar Link pending
Show.js Edgar Link pending
rvmd-20230930_lab.xml Edgar Link unprocessable
rvmd-20230930_pre.xml Edgar Link unprocessable
rvmd-20230930_htm.xml Edgar Link completed